Avacta Group PLC (AVCT:AIM) presented an investor update detailing encouraging Phase 1B data for ferridoxorubicin (AVA6000) in patients with advanced salivary gland cancers, reinforcing the strength of its Precision® FAP-activated drug delivery platform. The company reported that the Phase 1B cohort (19 efficacy-evaluable patients) continues to demonstrate a favourable safety profile consistent with Phase 1A, notably eliminating severe cardiac toxicity associated with conventional doxorubicin and significantly reducing haematologic and gastrointestinal toxicities, even with prolonged dosing. Efficacy remains highly encouraging, with a 90% disease control rate, including partial and minor responses, and most patients remaining on treatment with median progression-free survival (PFS) not yet reached. Translational and biopsy data showed marked tumour-selective accumulation of released doxorubicin versus plasma, exceeding concentrations required to kill salivary gland cancer cells in vitro, even in tumours with low FAP expression—providing strong proof of mechanism and supporting broader platform applicability. Management highlighted that these results de-risk progression into a planned randomised Phase 2/3 trial using PFS and overall survival as primary endpoints versus investigator’s choice chemotherapy, aligned with global treatment guidelines where no standard of care exists. Enrollment in Phase 1B continues toward up to 30 patients, with further survival updates expected in the first half of 2026, positioning AVA6000 as a potentially differentiated oncology asset with meaningful clinical benefit driven by durable disease stabilisation rather than tumour shrinkage alone.